News

A look at the effect that PPACA will have on part-time employees.

As the 2012 President Election nears, the candidates focus on Medicare and PPACA.

Looking at the next several years, administrative services only agreements appear to be the most profitable line of business.

A look at ACOs indicates that success will depend on managing risks and choosing the best possible partners.

Dual eligibles are a key population in healthcare and can be an area of important growth, but success is not guaranteed.

The decision of whether or not to expand Medicaid might seem like a cut-and-dried issue, but a closer look indicates that the issue isn't s simple.

As the market has reduced its emphasis on employer benefits, insurers need to focus on why consumers choose specific plans.

A balance between security and functionality is needed to drive mHealth.

Medical organizations take DNA patent claims to the Supreme Court to determine eligibility.

MA plans can use multiple data tools to improve predictive-modeling expertise.

FDA approved regorafenib (Stivarga, Bayer HealthCare) tablets for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with currently available therapies (including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and if KRAS wild type, an anti-EGFR therapy).

FDA has given priority review to an additional indication for lubiprostone (Amitiza, Sucampo Pharmaceuticals and Takeda) for the treatment of opioid-induced constipation (OIC) in patients with chronic, non-cancer pain.

The National Committee on Quality Assurance has released a new ranking of nearly 500 private health insurance plans.

Watson Laboratories issued a voluntary nationwide recall for 2 lots of hydrocodone bitartrate and APAP Tablets, USP 10 mg/500 mg. Hydrocodone bitartrate and acetaminophen 10 mg/500 mg tablets are indicated for the relief of moderate to moderately severe pain.

FDA has approved aflibercept (Eylea, Regeneron) injection for the treatment of macular edema following central retinal vein occlusion (CRVO). The recommended dose for Eylea is 2 mg every 4 weeks (monthly).

FDA approved a new indication for denosumab (Prolia, Amgen) as a treatment to increase bone mass in men with osteoporosis at high risk for fracture.

FDA notified healthcare professional about a possible increased failure of heart risk with pramipexole (Mirapex).

FDA has granted fast-track designation for the development of AVI-7288 and AVI-7537 (Sarepta Therapeutics), for the treatment of Marburg virus and Ebola virus, respectively.

FDA is warning consumers not to use Intestinomicina (Laboratorios Lopez), a drug product manufactured in El Salvador and marketed as a treatment for infectious diarrhea and acute gastrointestinal infections. Consumers who have purchased this product should immediately stop taking it and consult with a healthcare provider.

FDA has approved poly-ureaurethane 16% (Nuvail, Innocutis) nail solution to help manage fragile, damaged or brittle nails with cracking or splitting, a condition medically referred to as "nail dystrophy."

Consumers say that choosing healthcare benefits is the most difficult major life decision behind saving for retirement.

Researchers at Weill Cornell Medical College have discovered that an off-patent anti-inflammatory drug kills both replicating and non-replicating drug resistant tuberculosis in the laboratory.

Since posting its lowest annual growth rate in more than six years, the average cost of healthcare services accelerated in May and June.

The U.S. can learn from ways other countries slow prescription drug spending growth, according to a new policy analysis from the National Institute for Health Care Reform (NIHCR)

The Aetna Innovation Labs were created to test specific initiatives, determine success rates and impact, and expand programs that show promise.

Survey taker says payers are the only winners in healthcare reform; calls ACO member rules silly.

HealthPartners and Park Nicollet Health Services, have decided to combine to create an integrated healthcare delivery and financing powerhouse.

FDA's Cardiovascular and Renal Drugs Advisory Committee recommended against approving lixivaptan (CRTX 080, Cornerstone Therapeutics), for the treatment of symptomatic hypervolemic and euvolemic hyponatremia associated with heart failure and syndrome of inappropriate antidiuretic hormone, respectively.